Press release
Metastatic Prostate Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharma, Tavanta Therapeutics, Candel Therapeutics
"Metastatic Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate Cancer Market.
The Metastatic Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Metastatic Prostate Cancer Pipeline Report: https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Metastatic Prostate Cancer treatment therapies with a considerable amount of success over the years.
• Metastatic Prostate Cancer companies working in the treatment market are Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharmaceuticals, Tavanta Therapeutics, Candel Therapeutics, Jiangsu Hengrui Pharmaceuticals, and others, are developing therapies for the Metastatic Prostate Cancer treatment
• Emerging Metastatic Prostate Cancer therapies in the different phases of clinical trials are- 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others are expected to have a significant impact on the Metastatic Prostate Cancer market in the coming years.
• In May 2025, Janux Therapeutics initiated Phase Ib expansion studies with JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial targeting advanced metastatic castration-resistant prostate cancer (mCRPC). This open-label, multicenter Phase I trial is designed to evaluate the tolerability, pharmacodynamics, safety, preliminary efficacy, and pharmacokinetics of JANX007 as a standalone treatment or in combination therapy for adults with advanced mCRPC.
• In February 2025, Halda Therapeutics, a clinical-stage biotech company developing a new class of cancer treatments known as RIPTACTM (Regulated Induced Proximity Targeting Chimeras) therapeutics, announced today that the first patient has received dosing in the initial Phase 1/2 first-in-human clinical trial (NCT06800313). This trial is designed to assess the safety and tolerability of HLD-0915 for treating metastatic castration-resistant prostate cancer (mCRPC).
• In February 2025, Israeli pharmaceutical company RedHill Biopharma launched a placebo-controlled Phase II trial to evaluate the combination of opaganib and darolutamide for treating metastatic castrate-resistant prostate cancer (mCRPC). The study, involving 80 male participants, aims to assess whether opaganib can boost the effectiveness of standard androgen receptor pathway inhibition (ARPI) treatments
• In February 2025, Halda Therapeutics, a clinical-stage biotechnology company developing a new class of cancer therapies known as RIPTACTM (Regulated Induced Proximity Targeting Chimeras), announced today that the first patient has been dosed in its Phase 1/2 clinical trial (NCT06800313). This trial is designed to assess the safety and tolerability of HLD-0915 in treating metastatic castration-resistant prostate cancer (mCRPC).
• In December 2024, Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company dedicated to developing multimodal biological immunotherapies for cancer treatment, today announced the results of a multicenter Phase 3 clinical trial assessing the efficacy of CAN-2409 viral immunotherapy in patients with localized prostate cancer.
• In December 2024, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company specializing in multimodal biological immunotherapies for cancer treatment, has announced results from a multicenter Phase 3 clinical trial assessing CAN-2409 viral immunotherapy in patients with localized prostate cancer.
• In November 2024, The US Food and Drug Administration (FDA) has accepted Bayer's supplemental new drug application (sNDA) for its oral androgen receptor inhibitor (ARi), Nubeqa (darolutamide), for treating metastatic hormone-sensitive prostate cancer (mHSPC). The therapy is used in combination with androgen deprivation therapy (ADT). The sNDA submission is supported by positive findings from the Phase III ARANOTE trial, where the combination treatment achieved its primary endpoint by significantly improving radiological progression-free survival (rPFS).
• In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
• In August 2024, Nuvation Bio announced that the US Food and Drug Administration has approved its investigational new drug application to assess NUV-1511, the first clinical candidate developed from the company's innovative drug-drug conjugate (DDC) platform.
Metastatic Prostate Cancer Overview
Metastatic prostate cancer is an advanced stage of prostate cancer in which cancer cells spread from the prostate gland to other parts of the body, such as the bones, lymph nodes, liver, or lungs. This occurs when cancer cells break away from the primary tumor and travel through the bloodstream or lymphatic system to form secondary tumors. Symptoms may include bone pain, difficulty urinating, fatigue, and weight loss. Treatment for metastatic prostate cancer focuses on slowing the cancer's progression, managing symptoms, and improving quality of life, using options like hormone therapy, chemotherapy, immunotherapy, and targeted therapies.
Get a Free Sample PDF Report to know more about Metastatic Prostate Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Metastatic Prostate Cancer Drugs Under Different Phases of Clinical Development Include:
• 177Lu-PSMA-I&T: Curium
• Opevesostat (MK-5684; ODM-208): Merck/ Orion
• Mevrometostat (PF-06821497): Pfizer
• TRUQAP (capivasertib, AZD5363): AstraZeneca
• 177Lu-DOTA-rosopatamab (TLX591): Telix Pharmaceuticals
• TAVT-45 (abiraterone acetate): Tavanta Therapeutics
• Saruparib (AZD5305): AstraZeneca
• CAN-2409 (aglatimagene besadenovec): Candel Therapeutics
• Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
Metastatic Prostate Cancer Route of Administration
Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Metastatic Prostate Cancer Molecule Type
Metastatic Prostate Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Metastatic Prostate Cancer Pipeline Therapeutics Assessment
• Metastatic Prostate Cancer Assessment by Product Type
• Metastatic Prostate Cancer By Stage and Product Type
• Metastatic Prostate Cancer Assessment by Route of Administration
• Metastatic Prostate Cancer By Stage and Route of Administration
• Metastatic Prostate Cancer Assessment by Molecule Type
• Metastatic Prostate Cancer by Stage and Molecule Type
DelveInsight's Metastatic Prostate Cancer Report covers around 85+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Metastatic Prostate Cancer product details are provided in the report. Download the Metastatic Prostate Cancer pipeline report to learn more about the emerging Metastatic Prostate Cancer therapies
https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Metastatic Prostate Cancer Therapeutics Market include:
Key companies developing therapies for Metastatic Prostate Cancer are - MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, and others.
Metastatic Prostate Cancer Pipeline Analysis:
The Metastatic Prostate Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Prostate Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer Treatment.
• Metastatic Prostate Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Prostate Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Metastatic Prostate Cancer drugs and therapies
https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Metastatic Prostate Cancer Pipeline Market Drivers
• Growing Incidence of Prostate Cancer, Innovative Therapeutic Developments, Government and Non-Profit Funding Support, Aging Population, are some of the important factors that are fueling the Metastatic Prostate Cancer Market.
Metastatic Prostate Cancer Pipeline Market Barriers
• However, High Cost of Drug Development, Complex Disease Mechanism, Regulatory Hurdles, Adverse Side Effects of Treatments, and other factors are creating obstacles in the Metastatic Prostate Cancer Market growth.
Scope of Metastatic Prostate Cancer Pipeline Drug Insight
• Coverage: Global
• Key Metastatic Prostate Cancer Companies: Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharmaceuticals, Tavanta Therapeutics, Candel Therapeutics, Jiangsu Hengrui Pharmaceuticals, and others
• Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others
• Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies
• Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers
Request for Sample PDF Report for Metastatic Prostate Cancer Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Metastatic Prostate Cancer Report Introduction
2. Metastatic Prostate Cancer Executive Summary
3. Metastatic Prostate Cancer Overview
4. Metastatic Prostate Cancer- Analytical Perspective In-depth Commercial Assessment
5. Metastatic Prostate Cancer Pipeline Therapeutics
6. Metastatic Prostate Cancer Late Stage Products (Phase II/III)
7. Metastatic Prostate Cancer Mid Stage Products (Phase II)
8. Metastatic Prostate Cancer Early Stage Products (Phase I)
9. Metastatic Prostate Cancer Preclinical Stage Products
10. Metastatic Prostate Cancer Therapeutics Assessment
11. Metastatic Prostate Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Metastatic Prostate Cancer Key Companies
14. Metastatic Prostate Cancer Key Products
15. Metastatic Prostate Cancer Unmet Needs
16 . Metastatic Prostate Cancer Market Drivers and Barriers
17. Metastatic Prostate Cancer Future Perspectives and Conclusion
18. Metastatic Prostate Cancer Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Metastatic Prostate Cancer Market https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Metastatic Prostate Cancer Epidemiology https://www.delveinsight.com/report-store/metastatic-prostate-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Metastatic Prostate Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Cervical Dysplasia Market: https://www.delveinsight.com/report-store/cervical-dysplasia-market-insights
• Hypogonadism Market: https://www.delveinsight.com/report-store/hypogonadism-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Non-hodgkin's Lymphoma Market: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-market
• Substance Use Disorder Market: https://www.delveinsight.com/report-store/substance-use-disorder-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Prostate Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharma, Tavanta Therapeutics, Candel Therapeutics here
News-ID: 4054195 • Views: …
More Releases from DelveInsight Business Research
Metastatic Triple Negative Breast Cancer Market to Show Remarkable Growth Trends …
DelveInsight's "Metastatic Triple Negative Breast Cancer Patient Pool Analysis, Market Size and Market Forecast APAC - 2034′′ report offers an in-depth understanding of the Metastatic Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Metastatic Triple Negative Breast Cancer market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).
To Know in detail about the Metastatic Triple Negative Breast Cancer market outlook, drug uptake,…
Methylmalonic Acidemia Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Ap …
(Albany, USA) DelveInsight's "Methylmalonic Acidemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Methylmalonic Acidemia, historical and forecasted epidemiology as well as the Methylmalonic Acidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The Methylmalonic Acidemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Methylmalonic…
Familial Mediterranean Fever Treatment Market 2034: Clinical Trials, EMA, PDMA, …
(Albany, USA) DelveInsight's "Familial Mediterranean Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Familial Mediterranean Fever, historical and forecasted epidemiology as well as the Familial Mediterranean Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Familial Mediterranean Fever Market Share @ Familial Mediterranean Fever Market Outlook- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from…
Hypercholesterolemia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Me …
(Albany, USA) DelveInsight's "Hypercholesterolemia Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the hypercholesterolemia market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging hypercholesterolemia drugs, the hypercholesterolemia pipeline analysis report provides a 360° view of the therapeutics…
More Releases for Metastatic
Metastatic Melanoma Cancer Diagnostics Market Analysis and Forecasts to 2031
Metastatic Melanoma Cancer Diagnostics Market 2022
The global Metastatic Melanoma Cancer Diagnostics Market is expected to grow on an impertinent note in the next 10 years. It could witness a CAGR of 8% and reach US$ 2.9 Bn by 2021 - 2031. Data processing through Big Data is on the anvil. Clinical software solutions are there to help out, taking the help of Big Data. Thus, data accumulation as well as…
Sacituzumab Govitecan Approval for Advanced or Metastatic Urothelial Cancer
On April 13, 2021, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Sacituzumab Govitecan (from Gilead Sciences) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.
Sacituzumab govitecan is a first-in-class Trop-2-directed antibody-drug conjugated to a topoisomerase I inhibitor (SN-38). Trop-2 receptor, a protein frequently expressed in multiple types…
Global Metastatic Melanoma Treatment Market Growth 2020-2025
The recent COVID-19 report added by GLOBAL INFO RESEARCH gives a detailed account of the drivers and restraints in the global Metastatic Melanoma Treatment market. The research report, title[Global and China Metastatic Melanoma Treatment Market 2020 by Company, Type and Application, Forecast to 2025] presents a comprehensive take on the overall market. Analysts have carefully evaluated the milestones achieved by the global Metastatic Melanoma Treatment market and the current trends that are likely…
Metastatic Prostate Cancer Therapeutic and Disease Pipeline Review H2
Summary
“Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Metastatic Prostate Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Prostate Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end…
Metastatic Melanoma Market Growth with Worldwide Industry Analysis to 2024
A severe form of cancer, melanoma is commonly known as skin cancer. The population residing at higher altitude levels or in the close proximity to the equator, is the most susceptible to melanoma, as the symptoms are prominently initiated post-exposure to UV radiation that results in blistering sunburns. If diagnosed early in stage 0, melanoma can be surgically cured to almost 100%; however, when the disease metastizes in a body,…
Metastatic Hormone Refractory Prostate Cancer Market Lucrative Technological bre …
Cancer is one of the most fatal and chronic disorders, in which, there is development of tumor due to uncontrolled growth of cells in particular part of the body. Cancer is highly hazardous disease, in which, the mortality rate is extremely high, due to highly invasive nature and prolonged duration of disease.
Metastatic hormone refractory prostate cancer is the cancer of prostate glands. Prostate cancer is the most common form…
